This article has Open Peer Review reports available.
The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study
© Schovanek et al.; licensee BioMed Central Ltd. 2014
Received: 23 January 2014
Accepted: 7 July 2014
Published: 21 July 2014
Succinate dehydrogenase subunit B (SDHB) mutations are associated with aggressive pheochromocytoma (PHEO)/paraganglioma (PGL) behavior, often resulting in metastatic disease and fatal outcomes. These tumors are often larger, extra-adrenal, and contain lower catecholamine concentrations than other hereditary PHEOs/PGLs. This study evaluated the size and age at diagnosis of primary SDHB-related PHEOs/PGLs as independent predictors of their metastatic behavior and outcome (survival).
One hundred six patients with SDHB mutation-related PHEO/PGL were included in this retrospective study. The recorded largest diameters, locations, and patient ages at initial diagnosis of SDHB-related primary tumors were analyzed in the context of time to metastasis and patient survival.
First, the development of metastatic disease in patients with primary tumors ≥4.5 cm was significantly earlier than in patients with smaller tumors (P = 0.003). Second, patients with primary tumors larger than 5.5 cm also had worse overall survival than patients with smaller tumors (P = 0.008). Third, age at initial diagnosis was found to be an independent predictor of patient survival (PHEOs: P = 0.041; PGLs: P < 0.001). Fourth, we did not observe a significant difference in survival based on the specific SDHB mutations or patient sex.
Receiver operating characteristic curves established 4.5 cm as the best value to dichotomize the primary SDHB-related PHEO/PGL in order to evaluate the development of metastatic disease and 5.5 cm as the best value for survival prediction. Subsequently, the size of the primary tumor was found as an age-independent predictor of patient survival and metastases development in PGL. In both PHEO and PGL, age at diagnosis was found to be a size-independent predictor of patient survival. No significant difference was found in metastases development or patient survival between males and females or among specific SDHB mutations. This data further extends and supports previous recommendations that carriers with SDHB mutations must undergo early and regular evaluations to detect PHEO/PGL in order to achieve the best clinical outcome.
According to the 2004 WHO classification of tumors, pheochromocytomas (PHEOs) arise from chromaffin cells of neural crest origin in the adrenal medulla. Closely related paragangliomas (PGLs) arise from cells of sympathetic or parasympathetic paraganglia . These tumors synthesize catecholamines that are metabolized to metanephrines, which are preferentially used in the biochemical diagnosis of these tumors .
Mutations in succinate dehydrogenase subunit B (SDHB), first described by the pioneering work of Astuti et al. in 2001 , have been linked to more aggressive tumor behavior, presenting with a higher metastatic rate than other PHEOs/PGLs [3–7]. The rate of metastasis of SDHB-related PHEOs/PGLs has been reported to be between 34%  and 71% , with a 5-year survival rate of 36% after the diagnosis of metastasis . Other SDHx mutations have approximate metastatic rates as follows: SDHA, 0-14%; SDHC, rarely malignant; SDHD, <5% . In addition, regardless of SDHB mutation status, tumor size has also been shown to be related to developing metastatic disease . Recently, Eisenhofer and colleagues have described an increase in the likelihood of metastases in PHEOs from less than 6% for tumors smaller than 5 cm to over 50% in tumors larger than 10 cm; for PGLs, the rate of malignancy increases to over 80% for tumors larger than 9 cm. However, in their study, the genetic background was not considered .
While SDHB mutations are considered powerful predictors of malignancy, it is unclear why SDHB-related PHEOs/PGLs in particular are more aggressive, often metastatic, and ultimately fatal, even though some other hereditary PHEOs/PGLs are also pseudohypoxic and belong to the same Cluster I [13, 14]. Some unique insights into the presentation and pathogenesis of these tumors have been published recently by Eisenhofer et al. [12, 15], Loriot et al. , and Amar et al. [5, 9]. These studies either confirmed or first showed that SDHB-related PHEOs/PGLs are most commonly extra-adrenal and larger at first presentation, with a characteristic noradrenergic and/or dopaminergic biochemical phenotype, as well as much lower catecholamine tumor concentrations than any other sporadic or hereditary PHEOs/PGLs. As a result of this lower catecholamine content, SDHB patients may initially present with only mild clinical symptoms that do not become worrisome until a sufficient amount of catecholamines is released, often in cases of already large primary tumors.
Of the unique SDHB-related PHEO/PGL characteristics described above, extra-adrenal location, age at initial presentation, size of the primary tumor, and elevated methoxytyramine levels were introduced and confirmed as risk factors for the metastatic behavior of PHEOs/PGLs [11, 17–19]. Therefore, it has been recommended that patients with SDHB-related, large, or extra-adrenal PHEOs/PGLs should have more frequent and lifelong follow-up .
In the present study, we initially used receiver operating characteristic (ROC) curves to establish cut-off sizes for evaluation of the development of metastases and patient survival. We hypothesized that even in the presence of an SDHB mutation, smaller tumors would have a statistically significantly lower metastatic potential and longer patient survival than larger tumors. Subsequently we created Cox regression models aiming to establish whether those parameters could also be considered as independent predictors of PHEO/PGL metastatic behavior and patient outcome. The effect of having a specific SDHB gene mutation, adrenal or extra-adrenal tumor location, and their occurrence in males or females were also analyzed statistically. Finally, survival and metastatic potential parameters, including the presence of synchronous and metachronous metastases, were evaluated for both 5-year and overall survival.
We performed a single center retrospective study, evaluating only patients with SDHB-related PHEOs/PGLs seen for evaluation or treatment at the National Institutes of Health (NIH), a referral center for these tumors. Imaging, surgical, and pathological study reports were carefully reviewed in order to collect the most accurate information about the patients. The follow-up data and information were collected based on patients’ regular follow-up visits at NIH or from patients’ relatives who reported their death. All patients provided written informed consent. The study was conducted at the NIH under Institutional Review Board (IRB)-approved protocol 00-CH-0093.
Metastases were confirmed either by surgery or by anatomical and PHEO/PGL-specific functional imaging studies. When there was evidence of lesions in areas where chromaffin cells are not present, these lesions were considered metastatic. For the purposes of the present study, when the metastases were observed together with a recurrent tumor, the tumor was marked as metastatic; recurrences were not evaluated. We use the term synchronous metastases to describe the occurrence of metastases discovered at initial diagnosis or within 6 months after the primary tumor diagnosis. Its complementary group, patients without synchronous metastases, was divided into those developing metastases after 6 months and those who did not develop any detectable metastases during the data collection period. The metastases developing after 6 months from initial diagnosis are characterized as metachronous . The time to metastasis parameter is the interval between the initial diagnosis and the diagnosis of metastatic disease (defined as 0 for those with synchronous metastases).
For analyses of the effect of the size of the primary tumor for the development of metastases, we used the largest diameter size of 4.5 cm as a cutoff point, the optimal value (which maximized the sum of the sensitivity and specificity) based on ROC analysis; using this cutoff, the Area Under the Curve (AUC) = 0.782, sensitivity = 80.5%, specificity = 69%. For survival analysis, we dichotomized the patient cohort using the largest diameter size of 5.5 cm, the optimal cutoff point from ROC analysis for this endpoint (AUC = 0.663, sensitivity = 87.0%, specificity = 49.5%). This value divided the patients almost equally (Additional file 1: Figure S1). Alternatively, for some analyses the patients were divided into four nearly equal-sized groups according to the size of the primary tumor (≤4 cm, 4–6 cm, 6–9 cm, >9 cm). Analyses of the effects of various parameters on the time to metastases and for survival used Kaplan-Meier curves to graphically represent the results, with group comparisons based on the standard logrank test (to compare 2 groups), the trend version of it (to compare more than 2 groups that are ordered), or stratified versions of these (to adjust for a second parameter, such as PGL vs. PHEO). Survival analyses were reported either for total survival or for survival truncated at 5 years (i.e. anyone whose observation time was longer than 5 years was considered censored at 5 years); the same applied for “survival” analyses of time to metastases.
To analyze the mutual effects of age at diagnosis and the size of the primary tumor on survival, we used Cox regression models, with 5 ordered categories for age (defined by cutpoints at 20, 30, 40, 50 years old) and the aforementioned 4 ordered categories for size. Cox regression was also used to estimate the relative hazard rates for the 4 ordered size categories. For an alternative nonparametric, model-free estimate of the probability of death or metastases vs. tumor size, observations were divided into bins and the lowess smoother was applied to the proportions of outcomes in the bins. All survival results used death due to disease as the endpoint. All P-values were two-sided.
Patient and tumor characteristics
Comparison of the 4 tumor size groups
Type of tumor
Size of primary tumor
<= 4 cm
4 - 6 cm
6 - 9 cm
> 9 cm
No. of patients by tumor size group [%]
0.034 (PGL vs. PHEO)
Probability of 5-year survival [%]
Years to death (median)
Survival Hazard Ratio
No. of deceased patients [%]
Median age at diagnosis
Median year of diagnosis
Years to metastases (median)
Probability of 5-year “metastases-free interval” [%]
Probability of 10-year “metastases-free interval” [%]
Development of metastatic disease
Seventy-seven out of our 106 patients (72.6%) were diagnosed with metastatic disease over the course of their disease in the present study. Twenty-eight patients (26.4%) developed metastatic disease at the time of their primary tumor diagnosis or within six months (synchronous metastases); their median age at the initial diagnosis was 31.5 years; the median size of their primary tumor was 7.5 cm. Of the 78 patients not presenting with synchronous metastases, 49 (46.2% of total) went on to develop metachronous metastases, within the median time to metastases of 5 years; their median age at the initial diagnosis was 30 years; their median size of their primary tumors was 7.0 cm. For the remaining 29 (27.4% of total) patients who never developed metastatic disease, the median age at initial diagnosis was 29 years; their median size of the primary tumor was only 3.8 cm. The size of the primary tumors was found to be highly statistically different among the 3 groups described above (ANOVA, P < 0.001).
Patients with SDHB-related PHEO or PGL did not differ in the time to the development of metastasis (P = 0.54), and the probability of a 5-year metastasis-free interval among those without synchronous metastasis was similar (48.2% for PGL and 55.0% for PHEO).As described in Material and Methods, we used an ROC curve to establish an optimal cut-off size of the primary tumor in regards to the development of any metastases; the primary tumor size of 4.5 cm was the size that maximized the sum of the sensitivity and specificity to develop metastatic disease. The patients with primary tumors <4.5 cm had a median time to develop metachronous metastases of 8 years (CI 95%, 3 years to infinity), while those with larger tumors (≥4.5 cm) had a median time of only 2 years (CI 95%, 1 to 4 years; P = 0.003) (Figure 1C).
Effect of metastatic disease development on the survival rate
Regardless of the presence of PHEO or PGL or their primary size, the overall 5-year survival probability of patients with any type of metastases was 75.7% (CI 95%; 63%-84%). The 5-year survival probability from the initial diagnosis for patients who presented with synchronous metastases was 74.5%; for patients not presenting with synchronous metastases, it was 96.4% (P = 0.006). However, once the patient was diagnosed with metastatic disease, there was no significant difference in their 5-year survival from the time of that diagnosis (74.5% for patients with synchronous metastases and 77.0% for metachronous metastases; P = 0.42).
5-year survival probability of patients with tumors by tumor type (PHEO vs. PGL) and tumor size based on the presence of synchronous metastasis
Without synchronous metastases (n = 78)
Synchronous metastases (n = 28)
5-year/overall survival p-value
All tumors by type
PGL (n = 89)
97.9% (n = 66)
73.2% (n = 23)
PHEO (n = 17)
88.9% (n = 12)
80.0% (n = 5)
5-year/overall survival p-value
All tumors by size
<5.5 cm (n = 44)
95.2% (n = 37)
100% (n = 7)
> = 5.5 cm (n = 62)
97.1% (n = 41)
65.8% (n = 21)
5-year/overall survival p-value
PGLs by size
<5.5 cm (n = 41)
94.7% (n = 34)
100% (n = 7)
> = 5.5 cm (n = 48)
100% (n = 32)
60.9% (n = 16)
5-year/overall survival p-value
PHEOs by size
<5.5 cm (n = 3)
100% (n = 3)
> = 5.5 cm (n = 14)
85.7% (n = 9)
80.0% (n = 5)
5-year/overall survival p-value
Effect of primary tumor size on survival time
As mentioned previously, the primary tumor cut-off size for predicting development of metastases was 4.5 cm. We observed that all the patients who died due to disease suffered from metastatic PHEO/PGL spread. In order to provide the most precise and clinically relevant information regarding the outcome (survival time) of these patients, another ROC analysis was performed, which established a 5.5 cm diameter as the optimal cutoff size for predicting survival within the present cohort. Accordingly, for survival analyses, patients were divided into two groups: <5.5 cm and ≥5.5 cm. When we analyzed the effect of primary tumor size on the survival time of all patients with SDHB, we found that patients with primary tumors <5.5 cm had significantly longer overall survival than patients with ≥5.5 tumors (P = 0.008) (Figure 1C). When the two tumor types were analyzed separately, the effect of size was highly significant in PGLs (P = 0.012), but was not significant in PHEOs (P = 0.39). However, this size-based survival difference in PGLs was present only for overall survival; for survival during the initial 5-year interval the difference between patients with smaller and larger tumors was not significant (P = 0.12).
Effect of SDHBmutation type
In the present study, patients had a variety of SDHB mutation types: 13 had deletions (PGLs 11/PHEOs 2), 7 had frame-shift mutations (PGLs 4/PHEOs 3), 41 had missense mutations (PGLs 33/PHEOs 8), 24 had nonsense mutations (PGLs 20/PHEOs 4), and 21 had splice site mutations (PGLs 17/PHEOs 4). We did not find any significant differences in tumor size or survival time among different SDHB mutation types (P = 0.74 for size, P = 0.61 for survival time). The smallest tumors were found in the group of patients with frame-shift mutations, the largest tumors in patients with nonsense mutations.
Size and age as independent predictors of survival and metastatic disease
Cox regression models, including interaction terms (as described in the Methods section), were used to evaluate tumor size and patient age at primary diagnosis as separate survival predictors. In none of the analyses was the interaction term between these two factors significant and hence it was not included in the final analyses. In the PGL group the size of the primary tumor and the age at initial diagnosis were found to be strong independent predictors of patient survival (P = 0.007 and P < 0.001, respectively). In the PGL group, patients diagnosed at a younger age had better performance, as did patients with smaller tumors, defined by the ordered categories as described in the Methods section. Furthermore, in the PGL group age at diagnosis did not predict the time to development of metastases (P = 0.51), but the size of the primary tumor did (P = 0.003), with patients having larger tumors more likely to develop metastatic disease.
In the PHEO group age at diagnosis was an independent predictor of patient survival (P = 0.041) but not for the development of metastases (P = 0.21), similar to the situation in the PGL group. In PHEO, as for PGL, younger patients had the better performance. However, unlike the situation in PGL patients, in PHEO tumor size was not found to be an independent predictor of either patient survival (P = 0.49) or the development of metastases (P = 0.65).
In the present study of 106 patients with pathogenic SDHB germline mutations, we found that the size of the primary tumor is an age-independent predictor of patient survival and metastases development in PGL. In both PHEO and PGL, age at diagnosis was found to be a size-independent predictor of patient survival. Furthermore, the development of synchronous metastases significantly affected 5-year and overall survival in patients with PGL. Patients with PHEO had possibly worse, though it did not reach statistical significance, overall survival than those with PGL (P = 0.099); their survival was not affected by the size of the primary tumor or by synchronous metastases. We did not find a significant difference in metastases development or patient survival between males and females or among specific SDHB mutations.
The importance of the primary tumor size for patient prognosis in general oncology is well established, as manifested by the use of the TNM classification . Thus, previous studies have already agreed that the size of the primary tumor is an important predictor for patient survival and for the metastatic potential of PHEO/PGL, but none of these studies examined whether this finding was true of tumors with specific genetic backgrounds [12, 17, 19]. This study extends this knowledge, due to its unique design, to SDHB-related PHEO/PGL.
Evaluating two different parameters (survival and time to metastases) using ROC, we determined 2 optimal tumor size cut-offs for our study in order to provide more precise and clinically relevant information about these aggressive tumors. We established the optimal primary tumor size cut-off for the development of metastases as 4.5 cm; patients with smaller tumors developed metastases significantly later than patients with larger tumors. For the survival analyses, the patient cohort was separated into two groups, smaller tumors (<5.5 cm) and larger ones (≥5.5 cm), using a cut-point that was close to the median tumor size of PGLs, by far the larger of the two disease groups. Patients with smaller tumors had significantly better survival than patients with larger tumors, without separating PGL/PHEO. These two different cut-offs clinically show how the development of metastatic disease precedes disease mortality.
Alternatively the patients were divided into four groups according to the size of the primary tumor (≤4 cm, 4–6 cm, 6–9 cm, >9 cm); this division we considered clinically relevant and also resulted in groups of almost equal size (32/24/25/25). The percentages with synchronous metastases in these four groups were 22%, 13%, 28%, and 44%, respectively (trend P = 0.049, by exact test for contingency tables with ordered columns) (Table 1).
Studies evaluating exclusively metastatic PHEO/PGL patients have found that about one-third of these patients harbor pathogenic SDHB mutations [4, 9]; however, the reported metastatic rate in SDHB-related PHEO/PGL varies dramatically . In the present study we found it to be high, with 72.6% of the patients developing metastases over the course of the study, which is similar to the 71.7% previously reported in the study by Amar et al. . Consequently, the presence of an SDHB mutation was found to be an independent predictor of PHEO/PGL malignant behavior . Typical metastatic sites of SDHB-related PHEO/PGL include the bones, lungs, lymph nodes, and liver; multiple metastases are also possible .
Furthermore, in childhood and adolescence the incidence of PHEO/PGL is rare; however, when metastatic disease is diagnosed in these age groups, these patients have a high probability of having SDHB mutations . The present study showed better performance of younger patients and established the age at diagnosis as a survival predictor in patients with SDHB PHEO/PGL. Improved survival of younger patients was already reported in a study by Amar et al., but did not reach significance as an independent predictor .
The previously reported ratio between synchronous and metachronous metastases in various PHEOs/PGLs was almost equal (51%/49%) . In our study with only SDHB-related tumors, we observed predominantly metachronous rather than synchronous metastases (64%/36%), which could be due to the relatively long follow-up periods for our patients. We did not find a significant difference in the 5-year survival between patients after the diagnosis of synchronous or metachronous metastatic disease, which suggest that tumors with synchronous metastases are not inherently more aggressive.
There is still disagreement on the relative survival of patients with PHEO and PGL. A previous study, which did not classify the tumors based on genetic background, found overall survival to be significantly shorter in patients with PGLs than with PHEOs . A different study, which also did not consider the genetic background of the disease and included only metastatic PHEO/PGL, reported better survival of PGLs . Our study, including only patients with SDHB-related tumors, found that patients with PGLs had a better overall survival than patients with PHEOs. However the difference was not statistically significant, quite possibly due to the small number of PHEOs as opposed to PGLs in these patients with SDHB mutations (Figure 1A). While elucidating other possible differences between SDHB-related PHEO and PGL, we demonstrated that the size of the primary tumor for patients with PHEOs seems to be less important for patient survival than for PGL. We initially attributed this to the selected cut-off (5.5 cm), which was more representative of the size of primary PGLs (and divided them almost evenly) and divided the PHEOs quite unevenly. However, when we used 8 cm as a cutoff, the median size of PHEO primary tumors, there was again no survival difference in PHEOs between those with small vs. large tumors (P = 0.81) Significantly larger tumors in patients with PHEO than with PGL have been reported previously .
Our analysis clearly shows that the size of the primary tumor in PGLs predicts the development of metastatic disease and also affects patient survival, while the age at diagnosis predicts patient survival but not the development of metastases. In contrast, in the limited number of SDHB-mutated PHEOs, we found that the age at diagnosis is an important factor for survival, but the size of the primary tumor is not. The lack of an observed significant effect of primary tumor size in PHEOs is not in agreement with the previous observation of Zelinka et al. , who evaluated a larger sample of metastatic PHEOs, but did not focus on the genetic background of the PHEOs included in that study, both of which could explain this difference.
Given the status of the NIH PHEO/PGL program as a national and international referral center, our patient population is typically made up of clinically more severe and complicated cases, usually due to patients with underlying genetic backgrounds, which could possibly lead to some referral bias. Therefore, we were not able to establish a similarly sized cohort of apparently sporadic patients that would allow us to investigate whether these tumors would behave similarly to SDHB-related PHEO/PGL and to elucidate how exactly the presence of an SDHB mutation would affect the development of metastatic disease and patient survival when the size of the primary tumor is considered and compared to other PHEO/PGL types. Since the incidence of SDHB-related PHEOs is very low compared to SDHB-related PGLs, it was very difficult to reliably compare these two groups, and other significant findings might become more apparent if a larger number of PHEOs were available. Similarly, it was very difficult to evaluate the effect of size on metastases development in SDHB-related PHEOs, because there were only 17 such patients and only 4 of these (23.5%) did not develop any metastases. Of the 89 patients with PGL, 25 (28.09%) did not develop metastases during the follow-up period of this study. The PGL patient cohort also included patients with head and neck PGLs, because our main goal was to fully evaluate the SDHB patient population; however, a bigger patient cohort separating those patients from other PGL patients might provide further interesting results.
In summary, this unique study of patients with SDHB-related PHEO/PGL showed that the age at the primary diagnosis as well as the size of the primary tumor are two important independent prognostic factors. We did not find any difference based on the sex of the patient, but we did observe certain differences between SDHB-related PGLs and PHEOs. This data strongly supports our recommendations that all carriers with SDHB mutations should undergo early and regular evaluations to detect tumor(s) at an early stage to achieve the best clinical outcome with regards to their survival.
This research was supported by the Intramural Research Program of the Eunice Kennedy Shriver NICHD, NIH.
- DeLellis RA: Pathology and genetics of tumours of endocrine organs. 2004, Lyon: IARC PressGoogle Scholar
- Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, Eisenhofer G: Biochemical diagnosis of pheochromocytoma: which test is best?. JAMA. 2002, 287 (11): 1427-1434.View ArticlePubMedGoogle Scholar
- Astuti D, Latif F, Dallol A, Dahia PLM, Douglas F, George E, Sk√∂ldberg F, Husebye ES, Eng C, Maher ER: Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial Pheochromocytoma and to familial paraganglioma. Am J Hum Genet. 2001, 69 (1): 49-54.View ArticlePubMedPubMed CentralGoogle Scholar
- Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, Pacak K: High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006, 91 (11): 4505-4509.View ArticlePubMedGoogle Scholar
- Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, Bertagna X, Schlumberger M, Jeunemaitre X, Gimenez-Roqueplo AP, Plouin PF: Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007, 92 (10): 3822-3828.View ArticlePubMedGoogle Scholar
- Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PL, Elston M, Gimm O, Henley D, Herman P, Murday V, Niccoli-Sire P, Pasieka JL, Rohmer V, Tucker K, Jeunemaitre X, Marsh DJ, Plouin PF, Robinson BG: Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab. 2006, 91 (3): 827-836.View ArticlePubMedGoogle Scholar
- Karasek D, Shah U, Frysak Z, Stratakis C, Pacak K: An update on the genetics of pheochromocytoma. J Hum Hypertens. 2013, 27 (3): 141-147.View ArticlePubMedGoogle Scholar
- Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C: Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004, 292 (8): 943-951.View ArticlePubMedGoogle Scholar
- Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A, Niccoli-Sire P, Richard S, Rohmer V, Sadoul JL, Strompf L, Schlumberger M, Bertagna X, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP: Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005, 23 (34): 8812-8818.View ArticlePubMedGoogle Scholar
- Bope ET, Kellerman RD: Conn’s Current Therapy 2013: Expert Consult: Online. 2012, Philadelphia, Pa: Elsevier Health SciencesGoogle Scholar
- O’Riordain DS, Young WF, Grant CS, Carney JA, van Heerden JA: Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg. 1996, 20 (7): 916-921. discussion 922View ArticlePubMedGoogle Scholar
- Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, Mannelli M, Linehan WM, Adams K, Timmers HJ, Pacak K: Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012, 48 (11): 1739-1749.View ArticlePubMedGoogle Scholar
- Burnichon N, Vescovo L, Amar L, Libe R, de Reynies A, Venisse A, Jouanno E, Laurendeau I, Parfait B, Bertherat J, Plouin PF, Jeunemaitre X, Favier J, Gimenez-Roqueplo AP: Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011, 20 (20): 3974-3985.View ArticlePubMedGoogle Scholar
- Lopez-Jimenez E, Gomez-Lopez G, Leandro-Garcia LJ, Munoz I, Schiavi F, Montero-Conde C, de Cubas AA, Ramires R, Landa I, Leskela S, Maliszewska A, Inglada-Perez L, de la Vega L, Rodriguez-Antona C, Leton R, Bernal C, de Campos JM, Diez-Tascon C, Fraga MF, Boullosa C, Pisano DG, Opocher G, Robledo M, Cascon A: Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrin (Baltimore, Md). 2010, 24 (12): 2382-2391.View ArticleGoogle Scholar
- Eisenhofer G, Tischler AS, de Krijger RR: Diagnostic tests and biomarkers for Pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. Endocr Pathol. 2012, 23 (1): 4-14.View ArticlePubMedGoogle Scholar
- Loriot C, Burnichon N, Gadessaud N, Vescovo L, Amar L, Libe R, Bertherat J, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP, Favier J: Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations. J Clin Endocrinol Metab. 2012, 97 (6): E954-962.View ArticlePubMedGoogle Scholar
- Zelinka T, Musil Z, Duskova J, Burton D, Merino MJ, Milosevic D, Widimsky J, Pacak K: Metastatic pheochromocytoma: does the size and age matter?. Eur J Clin Invest. 2011, 41 (10): 1121-1128.View ArticlePubMedPubMed CentralGoogle Scholar
- Eisenhofer G, Lenders JW, Timmers H, Mannelli M, Grebe SK, Hofbauer LC, Bornstein SR, Tiebel O, Adams K, Bratslavsky G, Linehan WM, Pacak K: Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem. 2011, 57 (3): 411-420.View ArticlePubMedPubMed CentralGoogle Scholar
- Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C: Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011, 96 (3): 717-725.View ArticlePubMedGoogle Scholar
- Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, Kimura N, Mannelli M, McNicol AM, Tischler AS: Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007, 3 (2): 92-102.View ArticlePubMedGoogle Scholar
- Sobin LH, Gospodarowicz MK, Wittekind C, International Union against C: TNM classification of malignant tumours. 2010, Chichester, West Sussex, UK; Hoboken, NJ: Wiley-BlackwellGoogle Scholar
- Ricketts CJ, Forman JR, Rattenberry E, Bradshaw N, Lalloo F, Izatt L, Cole TR, Armstrong R, Kumar VK, Morrison PJ, Atkinson AB, Douglas F, Ball SG, Cook J, Srirangalingam U, Killick P, Kirby G, Aylwin S, Woodward ER, Evans DG, Hodgson SV, Murday V, Chew SL, Connell JM, Blundell TL, Macdonald F, Maher ER: Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat. 2010, 31 (1): 41-51.View ArticlePubMedGoogle Scholar
- King KS, Prodanov T, Kantorovich V, Fojo T, Hewitt JK, Zacharin M, Wesley R, Lodish M, Raygada M, Gimenez-Roqueplo AP, McCormack S, Eisenhofer G, Milosevic D, Kebebew E, Stratakis CA, Pacak K: Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol. 2011, 29 (31): 4137-4142.View ArticlePubMedPubMed CentralGoogle Scholar
- Goffredo P, Sosa JA, Roman SA: Malignant Pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades. J Surg Oncol. 2013, 107 (6): 659-664.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/523/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.